Breast cancer Trials in Qingdao, China
Conditions / Breast cancer / Qingdao, China
Breast cancer has been the subject of sustained clinical investigation across multiple research sites.
25 total trials for this combination
Showing top 10 of 25 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05346224 | A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06341283 | A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer | NOT_YET_RECRUITING | — |
| NCT04109066 | Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer | COMPLETED | PHASE3 |
| NCT05113251 | Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02225470 | Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | COMPLETED | PHASE3 |
| NCT06107686 | A Study of YL202 in Selected Patients With Advanced Solid Tumors | RECRUITING | PHASE2 |
| NCT05950945 | Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | RECRUITING | PHASE3 |
| NCT05629585 | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06846099 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903 | COMPLETED | PHASE1 |
| NCT06210776 | A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) | RECRUITING | — |